Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL)
Frequently Asked Questions About Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL)
Does Sol-Gel Technologies collaborate with other companies?
Yes, Sol-Gel Technologies actively seeks partnerships and collaborations with other biotech firms, research institutions, and pharmaceutical companies to enhance its R&D capabilities, expand its product pipeline, and leverage external expertise.
How can investors keep up-to-date with Sol-Gel Technologies?
Investors can stay informed about Sol-Gel Technologies through its investor relations website, where the company provides financial updates, press releases, and relevant information about ongoing clinical trials and product developments.
How does Sol-Gel Technologies ensure product safety?
Sol-Gel Technologies places a strong emphasis on safety and efficacy by conducting extensive preclinical studies followed by rigorous clinical trials. The company is committed to complying with all regulatory standards to ensure that its products are safe for consumer use.
Is Sol-Gel Technologies publicly traded?
Yes, Sol-Gel Technologies Ltd. is publicly traded on the Nasdaq stock exchange under the ticker symbol 'SLGL'. The company went public in 2018 to raise capital for its ongoing research and development efforts.
What are the company's future plans?
Sol-Gel Technologies plans to continue advancing its product pipeline and seeking new indications for its current technologies. The company aims to expand its market reach and enhance its portfolio through ongoing research and strategic partnerships.
What challenges does Sol-Gel Technologies face?
Like many biotech companies, Sol-Gel Technologies faces challenges such as regulatory hurdles, competition in the dermatology market, and the need for successful clinical trial results. The company is actively addressing these challenges through strategic planning and strong R&D efforts.
What differentiates Sol-Gel's products from competitors?
Sol-Gel Technologies differentiates its products through its unique drug delivery system, which enhances the efficacy and minimizes side effects compared to traditional formulations. The company’s focus on innovative, evidence-based treatments sets it apart in the competitive dermatology market.
What does Sol-Gel Technologies Ltd. do?
Sol-Gel Technologies Ltd. is a clinical-stage biotechnology company focused on developing and commercializing innovative dermatology products as well as drug formulations through its proprietary technology platforms. The company primarily aims to treat skin diseases, including acne, rosacea, and other related disorders.
What is Efsynty?
Efsynty is Sol-Gel Technologies’ proprietary topical gel formulation for the treatment of acne. It utilizes the company's sol-gel technology to enhance the delivery of active ingredients, providing a novel approach to treating this common skin condition.
What is Sol-Gel Technologies' approach to drug development?
Sol-Gel Technologies employs a science-driven approach to drug development, focusing on leveraging its advanced silicate technology to create effective and safe dermatology treatments. The company conducts rigorous clinical trials to validate the safety and efficacy of its products.
What is Sol-Gel's primary technology platform?
Sol-Gel's primary technology platform is centered around its proprietary silica-based drug delivery system. This platform uses sol-gel chemistry to create formulations that improve the bioavailability and efficacy of active ingredients in dermatological products.
What is the company's mission?
The mission of Sol-Gel Technologies is to revolutionize the treatment of dermatological conditions through innovative science and technology. The company strives to improve patient outcomes and quality of life by developing advanced therapeutic solutions.
What is Twyneo?
Twyneo is another key product from Sol-Gel Technologies, aimed at treating both acne and rosacea. This combination product incorporates two active ingredients and utilizes sol-gel technology to ensure optimal skin penetration and efficacy.
What markets does Sol-Gel Technologies serve?
Sol-Gel Technologies primarily serves the dermatological market, catering to patients with skin diseases such as acne and rosacea. The company aims to provide advanced treatment options that address unmet medical needs in these areas.
What products has Sol-Gel Technologies developed?
Sol-Gel Technologies has developed a range of products, with its leading candidates being novel topical treatments for acne and rosacea. The company’s most notable products include Efsynty and Twyneo, which are designed to effectively target these skin conditions.
What resources are available for patients interested in Sol-Gel's products?
Patients interested in Sol-Gel's products can access information on the company’s official website, including educational resources about their product offerings, clinical trial information, and ways to connect with healthcare providers for treatment options tailored to their needs.
What stage are Sol-Gel's products in regarding FDA approval?
As of the latest updates, Sol-Gel Technologies has filed for FDA approval of its leading products, Efsynty and Twyneo, and is undergoing the regulatory review process. The company is optimistic about the outcomes and is preparing for potential market launch upon receiving approval.
When was Sol-Gel Technologies Ltd. founded?
Sol-Gel Technologies Ltd. was founded in 2010. Since then, the company has been at the forefront of developing novel dermatological therapies using its unique formulation technology.
Where is Sol-Gel Technologies headquartered?
Sol-Gel Technologies is headquartered in Rehovot, Israel. This strategic location provides the company access to a robust network of innovation, expertise, and collaboration within the biotech industry.
Who are the key executives at Sol-Gel Technologies?
The executive team at Sol-Gel Technologies includes experienced leaders from the biotech and pharmaceutical industries, including the CEO, Dr. Alon Amir, and other senior executives with expertise in drug development, commercialization, and corporate governance.
What is the current price of Sol-Gel Technologies Ltd. - Ordinary Shares?
The current price of Sol-Gel Technologies Ltd. - Ordinary Shares is 7.235
When was Sol-Gel Technologies Ltd. - Ordinary Shares last traded?
The last trade of Sol-Gel Technologies Ltd. - Ordinary Shares was at 3:59 pm EDT on June 6th, 2025